OREANDA-NEWS. Cosmo Pharmaceuticals S.p.A. (“Cosmo”) announces the results of the preemptive offer to Cosmo shareholders of the shares with respect to which cash exit rights were exercised in connection with the resolution on the relocation of the registered seat from Italy to Luxembourg adopted by the Extraordinary Shareholders’ Meeting on November 14, 2014.

At completion of the offer period, 12 Cosmo shareholders elected to purchase 2’867 shares of the total of 104.931 shares with respect to which cash exit rights were exercised.

The 2’867 purchased shares will be delivered to purchasing shareholders against payment of the cash exit price of CHF 156.03 for each share. Payment needs to be received by the Company by April 16, 2015. The settlement date will be April, 20, 2015 (i.e. 180 days after the starting date of the withdrawal period). On the settlement date referred to above, Cosmo will also pay the cash exit price of CHF 156.03 per share for each of the residual shares and on the same date shareholders that exercised their exit rights will receive their corresponding payment.

Cosmo has not yet determined if the Company will exercise its right to offer on the market the net amount 102’064 remaining shares which it is purchasing under the exit rights rules.

About Cosmo Pharmaceuticals

Cosmo is a specialty pharmaceutical company that aims to become a global leader in the field of optimized therapies for selected Gastrointestinal and topically treated Skin Disorders. The company’s proprietary clinical development pipeline specifically addresses innovative treatments for IBD, such as Ulcerative Colitis and Crohn’s Disease, and Colon Infections. In addition, the Company is developing a diagnostic for the detection of colon cancer and a medical device for polyp excision as well as a new chemical entity for the topical skin treatment. Cosmo’s MMX® products that have reached the market are Lialda®/Mezavant®/Mesavancol®, a treatment for IBD that is licensed globally to Giuliani and Shire Limited and Uceris®, the first glucocorticosteroid indicated for the induction of remission in active, mild to moderate Ulcerative Colitis, licensed in US to Salix and in the Rest of the World except for Japan to Ferring. Cosmo’s proprietary MMX® technology is at the core of the Company’s product pipeline and was developed from its expertise in formulating and manufacturing gastrointestinal drugs for international clients at its GMP (Good Manufacturing Practice) facilities in Lainate, Italy. The technology is designed to deliver active ingredients in a targeted manner in the colon.